Elixir Pharmaceuticals Signs Option Agreement, Completes Equity Financing

Elixir Pharmaceuticals, Inc., announced the Company has entered into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Elixir following the successful completion of a Phase 2a clinical study of Elixir’s lead oral ghrelin antagonist, currently in preclinical, IND-enabling studies.
Morningstar